Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Vitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo-controlled trial.

Pace A, Giannarelli D, Galiè E, Savarese A, Carpano S, Della Giulia M, Pozzi A, Silvani A, Gaviani P, Scaioli V, Jandolo B, Bove L, Cognetti F.

Neurology. 2010 Mar 2;74(9):762-6. doi: 10.1212/WNL.0b013e3181d5279e.

PMID:
20194916
2.

A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results.

Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P, Kalofonos HP.

Support Care Cancer. 2006 Nov;14(11):1134-40. Epub 2006 Apr 19.

PMID:
16622646
3.

Neuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy.

Pace A, Savarese A, Picardo M, Maresca V, Pacetti U, Del Monte G, Biroccio A, Leonetti C, Jandolo B, Cognetti F, Bove L.

J Clin Oncol. 2003 Mar 1;21(5):927-31.

PMID:
12610195
4.

A pilot study on the relation between cisplatin neuropathy and vitamin E.

Bove L, Picardo M, Maresca V, Jandolo B, Pace A.

J Exp Clin Cancer Res. 2001 Jun;20(2):277-80.

PMID:
11484987
5.

Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.

Argyriou AA, Chroni E, Koutras A, Ellul J, Papapetropoulos S, Katsoulas G, Iconomou G, Kalofonos HP.

Neurology. 2005 Jan 11;64(1):26-31.

PMID:
15642899
6.

Interventions for preventing neuropathy caused by cisplatin and related compounds.

Albers J, Chaudhry V, Cavaletti G, Donehower R.

Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005228. Review. Update in: Cochrane Database Syst Rev. 2011;(2):CD005228.

PMID:
17253547
7.

Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation.

Argyriou AA, Chroni E, Koutras A, Iconomou G, Papapetropoulos S, Polychronopoulos P, Kalofonos HP.

J Pain Symptom Manage. 2006 Sep;32(3):237-44.

PMID:
16939848
8.

Interventions for preventing neuropathy caused by cisplatin and related compounds.

Albers JW, Chaudhry V, Cavaletti G, Donehower RC.

Cochrane Database Syst Rev. 2011 Feb 16;(2):CD005228. doi: 10.1002/14651858.CD005228.pub3. Review. Update in: Cochrane Database Syst Rev. 2014;3:CD005228.

9.

Retreatment with dose-dense weekly cisplatin after previous cisplatin chemotherapy is not complicated by significant neuro-toxicity.

van den Bent MJ, van Putten WL, Hilkens PH, de Wit R, van der Burg ME.

Eur J Cancer. 2002 Feb;38(3):387-91.

PMID:
11818204
10.

Vitamin E for prevention of oxaliplatin-induced peripheral neuropathy: a pilot randomized clinical trial.

Afonseca SO, Cruz FM, Cubero Dde I, Lera AT, Schindler F, Okawara M, Souza LF, Rodrigues NP, Giglio Ad.

Sao Paulo Med J. 2013;131(1):35-8.

11.

Vitamin E for prophylaxis against chemotherapy-induced neuropathy: a randomized controlled trial.

Pace A, Bove L, Jandolo B.

Neurology. 2005 Aug 9;65(3):501-2; author reply 501-2. No abstract available.

PMID:
16087937
12.

Protective effects of vitamin E on chemotherapy-induced peripheral neuropathy: a meta-analysis of randomized controlled trials.

Eum S, Choi HD, Chang MJ, Choi HC, Ko YJ, Ahn JS, Shin WG, Lee JY.

Int J Vitam Nutr Res. 2013;83(2):101-11. doi: 10.1024/0300-9831/a000149.

PMID:
24491883
13.

The use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial.

Kottschade LA, Sloan JA, Mazurczak MA, Johnson DB, Murphy BP, Rowland KM, Smith DA, Berg AR, Stella PJ, Loprinzi CL.

Support Care Cancer. 2011 Nov;19(11):1769-77. doi: 10.1007/s00520-010-1018-3. Epub 2010 Oct 9.

14.

Supplementation with antioxidant micronutrients and chemotherapy-induced toxicity in cancer patients treated with cisplatin-based chemotherapy: a randomised, double-blind, placebo-controlled study.

Weijl NI, Elsendoorn TJ, Lentjes EG, Hopman GD, Wipkink-Bakker A, Zwinderman AH, Cleton FJ, Osanto S.

Eur J Cancer. 2004 Jul;40(11):1713-23.

PMID:
15251161
15.

Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group.

Moore DH, Donnelly J, McGuire WP, Almadrones L, Cella DF, Herzog TJ, Waggoner SE; Gynecologic Oncology Group..

J Clin Oncol. 2003 Nov 15;21(22):4207-13.

PMID:
14615449
16.

Protective effect of erythropoietin and its carbamylated derivative in experimental Cisplatin peripheral neurotoxicity.

Bianchi R, Brines M, Lauria G, Savino C, Gilardini A, Nicolini G, Rodriguez-Menendez V, Oggioni N, Canta A, Penza P, Lombardi R, Minoia C, Ronchi A, Cerami A, Ghezzi P, Cavaletti G.

Clin Cancer Res. 2006 Apr 15;12(8):2607-12.

17.

Chemotherapy-induced peripheral neuropathy.

Hilkens PH, ven den Bent MJ.

J Peripher Nerv Syst. 1997;2(4):350-61. Review.

PMID:
10975744
18.

Chemotherapy-induced chromosomal damage in peripheral blood lymphocytes of cancer patients supplemented with antioxidants or placebo.

Elsendoorn TJ, Weijl NI, Mithoe S, Zwinderman AH, Van Dam F, De Zwart FA, Tates AD, Osanto S.

Mutat Res. 2001 Nov 15;498(1-2):145-58.

PMID:
11673080
19.

Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin.

Cassidy J, Paul J, Soukop M, Habeshaw T, Reed NS, Parkin D, Kaye SB.

Cancer Chemother Pharmacol. 1998;41(2):161-6.

PMID:
9443630
20.

Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial.

Guo Y, Jones D, Palmer JL, Forman A, Dakhil SR, Velasco MR, Weiss M, Gilman P, Mills GM, Noga SJ, Eng C, Overman MJ, Fisch MJ.

Support Care Cancer. 2014 May;22(5):1223-31. doi: 10.1007/s00520-013-2075-1. Epub 2013 Dec 22.

PMID:
24362907

Supplemental Content

Support Center